1.
N Engl J Med
; 388(15): 1435-1436, 2023 Apr 13.
Artículo
en Inglés
| MEDLINE
| ID: mdl-37043658
2.
3.
Cancers (Basel)
; 13(8)2021 Apr 16.
Artículo
en Inglés
| MEDLINE
| ID: mdl-33923396
RESUMEN
Primary central nervous system lymphoma (PCNSL) is a type of non-Hodgkin lymphoma limited to the central nervous system. It has a poor prognosis. Consensus has been reached on the treatment of newly diagnosed patients with high-dose methotrexate-based chemotherapy, but whether the addition of the monoclonal anti-CD20 antibody rituximab improves survival, as it does in systemic B-cell non-Hodgkin lymphoma, remains disputed. In this review, we reflect on the available evidence of the use of rituximab in PCNSL. Whether rituximab has any beneficial effect remains uncertain.
4.
Ann Hematol
; 96(10): 1759-1762, 2017 Oct.
Artículo
en Inglés
| MEDLINE
| ID: mdl-28779352